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Context: A subpopulation of hypothalamic neurons colocalize three neuropeptides, namely kiss-
peptin, neurokinin B (NKB), and dynorphin, collectively termed KNDy neurons. Animal studies
suggest they interact to affect pulsatile GnRH release (KNDy hypothesis); kisspeptin stimulates,
NKB modulates, and dynorphin (an opioid) inhibits.
Objective: To investigate the KNDy hypothesis in humans, we assessed for the first time the effects
of the coadministration of kisspeptin-54, NKB, and an opioid receptor antagonist, naltrexone, on
LH pulsatility (surrogate marker for GnRH pulsatility) and gonadotropin release.
Design, Setting, and Participants: This was an ethically approved prospective, single-blinded, placebo-
controlledstudy.Healthymalevolunteers (n5/group)attendedourresearchfacility foreight studyvisits.
Intervention and Main Outcome Measure: After 1 hour of baseline blood sampling, participants
received a different intervention at each visit: oral 50mgnaltrexone, 8-hour iv infusions of vehicle,
2.56nmol/kg  hNKB,0.1nmol/kg  hkissspeptin-54 (KP) aloneand in combination. Frequentblood
sampling tomeasure plasma gonadotropins and sex steroidswas conducted and LH pulsatility was
determined using blinded deconvolution analysis.
Results: All kisspeptin and naltrexone containing groups potently increased LH and LH pulsatility
(P  .001 vs vehicle). NKB alone did not affect gonadotropins. NKBKP had significantly lower
increases in gonadotropins comparedwith kisspeptin alone (P .01). NaltrexoneKPwas the only
group to significantly increase LH pulse amplitude (P  .001 vs vehicle).
Conclusions:Our results suggest significant interactions between the KNDy neuropeptides on LH pul-
satility and gonadotropin release in humans. This has important implications for improving our un-
derstanding of GnRH pulse generation in humans. (J Clin Endocrinol Metab 101: 3429–3436, 2016)
The field of reproductive neuroendocrinology has beenevolving rapidly over the last decade since the dis-
covery of the hypothalamic neuropeptide kisspeptin and
its role in puberty and reproduction (1, 2). Kisspeptin has
been shown to stimulate GnRH release and pulsatility.
Recent evidence suggests that kisspeptin may not work
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alone but in combination with two other neuropeptides,
neurokinin B (NKB) and dynorphin, collectively termed
KNDyneurons (3), to affectGnRHrelease andpulsatility.
NKB is a member of the tachykinin family and in humans
is encodedby the tachykinin-3 (TAC3) gene andacts at the
neurokinin-3 receptor (NK3R) encoded by the TACR3
gene. Dynorphin is an opioid that acts at the -opioid
receptor (KOR).
These three neuropeptides are found throughout the
brain; however, they colocalize in a particular neuronal
subpopulation in the arcuate nucleus (ARC) in mice (4),
rats (5, 6), sheep (7), goats (8), andmonkeys (9). TheARC
is an important hypothalamic area that affects GnRH se-
cretion and may represent the site of the elusive GnRH
pulse generator (10). Multiunit activity (MUA) volleys
near KNDy neurons in the ARC closely correspond with
LH pulses (8). This has led to the concept of the KNDy hy-
pothesis,whichsuggests thatKNDyneuronsintheARCmay
interact to control GnRH release and pulsatility (4).
KNDy neuropeptides have been studied individually
and affect LH secretion. Mutations in the genes encoding
for kisspeptin, NKB, and their receptors (KISS1, TAC3,
KISS1R, TACR3) result in hypogonadotrophic hypogo-
nadism (1, 2, 11), indicating that bothkisspeptin andNKB
are critical for normal GnRH secretion in humans and
subsequent puberty and reproduction. Kisspeptin has
been shown to act on kisspeptin receptors (KISS1R) ex-
pressedonGnRHneurons to stimulateGnRHrelease (12–
13), which subsequently stimulates gonadotropin secre-
tion (14). However, NKB’s effects have been more
variable, with some studies showing stimulatory or inhib-
itory effects on gonadotropins. It is now clear that sex
steroid milieu, pubertal status, and gender are important
factors that govern the effects of NKB on gonadotropin
release (15). Although the NKB receptor, NK3R, is not
largely expressed on GnRH neurons (16–18), it is ex-
pressed on KNDy neurons in the ARC, and therefore,
NKB is likely to act here to governGnRHrelease (4, 5, 17).
Endogenous opioids have an inhibitory role on LH se-
cretion. In particular the opioid dynorphin and agonists of
its receptor, KOR, have been shown to inhibit LH secre-
tion (4, 8, 19) aswell as inhibitingMUAin themedial basal
hypothalamus (8). Conversely, iv naloxone (an opioid re-
ceptor antagonist) increased MUA activity in the ARC as
well as LH (20), and specific KOR antagonists have been
shown to cause a rise in LH (21, 22). Thus, dynorphin is
thought to act at the level of the hypothalamus to inhibit
GnRH and subsequent gonadotropin secretion.
In summary, anatomical and functional data in animals
suggest that KNDy neuropeptides play an important role
to control GnRH release and pulsatility. In humans ana-
tomical studies also suggest that the KNDy neuropeptides
are colocalized in the infundibular nucleus (equivalent of
the ARC in humans) (23, 24). However, no previous stud-
ies have investigated the effects of combined administra-
tion of the KNDy neuropeptides on gonadotropin release
in humans.
Therefore, the aim of this study was to investigate the
KNDyhypothesis in humans by assessing for the first time
the effects of coadministrationofkisspeptin-54,NKB, and
an opioid receptor antagonist, naltrexone, on LH pulsa-
tility (surrogate marker for GnRH pulsatility in humans)
and gonadotropin release.
Materials and Methods
Ethics
Ethical approval was granted by the UK National Research
Ethics Committee-Central London (Research Ethics Committee
number 14/LO/1098). The study was performed in accordance
with the Declaration of Helsinki. Written informed consent was
obtained from all participants.
Subjects
Healthy male volunteers aged between 18 and 45 years old
were recruited from local newspaper advertisements (full details
given in the Supplemental Methods).
Peptides
Kisspeptin-54 was administered at 0.1 nmol/kg  h because
this dose has been shown to cause a rise in LH in healthy men
(14). NKB was administered at 2.56 nmol/kg  h because this
dose was biologically active and well tolerated in previous stud-
ies (25).
Naltrexone hydrochloride (a nonselective opioid receptor an-
tagonist) was administered as an oral tablet with water. Oral
naltrexone is rapidly absorbed with peak plasma levels achieved
after 1 hour (similar peak levels seenwith iv administration) (26)
and a half-life of 12 hours; thus, stable levels were achieved for
most of the study period (26, 27). Oral naltrexone 50 mg was
chosenbecause it hasbeen shown inotherhumanstudies to cause
a rise in LH at this dose (28, 29). Full details of kisspeptin-54,
NKB and naltrexone are detailed in the Supplemental Methods.
Protocol
Studies were conducted in our clinical investigation unit, and
participants were asked to refrain from strenuous exercise, sex-
ual activity, and alcohol consumption for the 24-hour period
preceding each study visit. The subjects were blinded but not the
investigators. Subjects arrived in themorningwere cannulated in
both forearms and asked to lie supine. The participants attended
eight study visits at least a week apart and received a different
treatment at each visit in random order. Figure 1 shows a sum-
mary of the protocol for each study visit and the treatments
received (Figure 1, A–H). After 1 hour of baseline blood sam-
pling, participants received either a naltrexone (NAL) 50-mg
tablet to swallow with water or an iv infusions of vehicle (gelo-
fusin), 2.56 nmol/kg  h NKB (NKB) or 0.1 nmol/kg  h kisspep-
tin-54 (KP) for 8 hours alone or in combination as outlined in the
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protocol diagram in Figure 1, A–H, and further explained in
Supplemental Table 1, in randomorder.Regular blood sampling
was commenced and continued for 8 hours to measure gonad-
otropins and sex steroids.
Because these peptides have never been coinfused in humans
previously, we based our sample size calculation on a previous
study in animals in which the effects of ip injections of NKB and
kisspeptin alone and then in combination on gonadotropin re-
lease were investigated in male mice (Corander et al [30]).
Analysis
Samples were analyzed for the measurement of LH, FSH, T,
and estradiol using automated chemiluminescent immunoassays
(Abbott Diagnostics). Reference ranges were as follows: LH,
4–14 IU/L; FSH,1.5–8 IU/L;T, 10–28nmol/L; and estradiol less
than 190 pmol/L. The respective intraassay and interassay co-
efficients of variation for each assay were 4.1% and 2.7% (LH);
4.1% and 3.0% (FSH); 4.2% and 2.8% (total T); and 3.3% and
3.0% (estradiol). Analytical sensitivities were: 0.5 IU/L (LH),
0.05 IU/L (FSH), 2 nmol/L (total T), and 37 pmol/L (estradiol).
Data analysis/statistical analysis
Statistical analysis of the data was performed by a statistician
(P.B.). For the purposes of analysis, the eight treatment combi-
nations were considered as eight different groups, rather than
splitting into the three constituent peptides. Due to the relatively
large number of combinations between
pairs of groups, only comparisons with a
value of P  .01 were considered statis-
tically significant.
LH, FSH, T and estradiol statistical
analysis. The analyses were performed
bymodeling the response of LH, FSH, T,
and estradiol over time for each treat-
ment group.To allow for the repeatmea-
surements over time, a multilevel linear
regression analysis was used as well as
two-level models with individual mea-
surements nested within patients. Treat-
ment group was considered to be a fixed
effect. The differing relationships over
time between treatment combinations
weredeterminedby examining the size of
the interaction between treatment and
time. A significant interactionwould im-
ply that the changes inoutcomeover time
varied between treatment groups. To al-
low for a flexible curved relationship be-
tween timeand theoutcomevariable, lin-
ear, squared, and cubic terms for time
were included if found to improve the fit.
The LH, FSH, T, and estradiol data sug-
gest that the best fit came by including
linear, squared, and cubic terms for time.
LH and FSH results were found to have
positively skewed distributions and thus
were analyzed on the log scale. T and
estradiol data were approximately nor-
mally distributed, and therefore, no data
transformation was performed. In view
of differing baseline sex steroid values
between participants, T and estradiol results were analyzed as a
change from baseline.
LH pulse number, amplitude, and approximate
entropy (ApEn) analysis
J.D.V. used a previously described, blinded deconvolution
method with 93% sensitivity and specificity to analyze LH pul-
satility (31). J.D.V. calculated the LH pulse number, amplitude
of each pulse, and the ApEn for each study visit. ApEn is a mea-
sure of orderliness of LH pulses (the lower the number, the more
ordered the pulses in the time series, with zero denoting perfect
orderliness) (31). To allow for repeatmeasurements, a statistical
analysis was performed using multilevel linear regression. Two-
level models were used with individual measurements nested
within patients. Treatment group was considered to be a fixed
effect.
Results
The participant’s characteristics, baseline gonadotropins,
and sex steroid levels are shown in Supplemental Table 2:
meanageSEM,32.93.9years, andmeanBMI,23.8
1.0. No participants reported any adverse effects.
Figure 1. Study protocol diagram. Five healthy male participants attended for eight study visits
at least a week apart and received a different treatment combination (A–H) in random order at
each visit. After 1 hour of baseline blood sampling every 15 minutes, the treatments were
initiated at t  0 hour: naltrexone (single 50 mg tablet) swallowed with water or 8-hour
infusions of vehicle, 2.56 nmol/kg  h NKB, or 0.1 nmol/kg  h kisspeptin-54 administered alone
or in combinations (A–H below) in random order. Oral naltrexone is rapidly absorbed with peak
plasma levels achieved after 1 hour and a half-life of 12 hours; thus, stable levels were achieved
for most of the study period (26, 27). Ten-minute blood sampling for gonadotropins and T and
hourly blood sampling for estradiol was commenced from the start of the treatment at t  0
hour and continued for the duration of the 8-hour study period, after which the infusions were
stopped and the study ended. Upward black arrows represent frequent blood sampling during
the study.
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LH results
The results suggested a very distinct pattern dividing
into two groups: those containing kisspeptin and those
without. Treatment combinations containing kisspeptin
(KP, NALKP, NKBKP, NALNKBKP) showed a
large rise in LH, which was highly significant compared
with vehicle (P  .001) over time up to around 360 min-
utes, after which the values levelled off (Figure 2).
In treatment combinations containing naltrexone but
not kisspeptin, there was a smaller but highly significant
rise in LH over time compared with vehicle in the NAL
(P .001) and NALNKB (P .001) groups. The NKB
group did not show a statistically significant rise in LH
over time compared with vehicle (P .75) (Figure 2). The
individual LH results from all participants is shown in
Supplemental Figure 1.
Given the sharp difference in LH, depending on
whether kisspeptinwas given, the focus of further analysis
was on the difference between the kisspeptin-only group
and the groups containing kisspeptin. There was a trend
toward an increase in LH in the NALKP group com-
paredwith kisspeptin alone (P .08).However, therewas
significantly lower increase in LH with the NKBKP
group (P  .006) compared with kisspeptin alone.
LH pulsatility: number of LH pulses
Most treatment groups achieved a significant increase
in LH pulse number compared with vehicle (P .001 for
all treatment groups, except KP only [P .007] and NKB
[P  .55]) (Figure 3).
There was no significant difference in comparing the
kisspeptin-containing groups with kisspeptin alone:
NALKP (P  .23), NKBKP (P  .04), and
NALNKBKP (P  .37).
LH pulsatility: pulse amplitude
Specific comparisons between each group and vehicle
showed that there was a significant rise in the LH pulse
amplitude only in the NALKP group compared with
vehicle (P  .001) (Supplemental Figure 2).
LH pulsatility: ApEn
ApEn is a measure of orderliness of LH pulses (the lower
thenumber, themoreordered thepulses) (31).TheApEn for
each treatment group is shown in Figure 4. All kisspeptin-
containing groups compared with vehicle showed a trend
toward lower ApEn values, indicating more ordered pulses,
but this reached the 1% significance level only for the
NALNKBKP group (NALNKBKP, P  .001; KP,
P .02, NALKP, P .02; NKBKP, P .04 vs vehicle).
In contrast, naltrexone-containing groups not contain-
ing kisspeptin had significantly higher ApEn compared
with vehicle (NAL, P  .001; NALNKB, P  .001),
indicating less ordered pulses. NKB alone had no signifi-
cant effects on ApEn compared with vehicle (P  .28).
Follicle-stimulating hormone
Similar to the LH results, any group containing kiss-
peptin (KP, NALKP, NKBKP, NALNKBKP) re-
sulted in a highly significant rise in FSH compared with
vehicle (P  .001) (Supplemental Figure 3).
In the nonkisspeptin-containing groups, only
NALNKB showed a significant rise in FSH compared
with vehicle (P  .002); the NAL alone group showed a
Figure 2. Effects of naltrexone (NAL), NKB, and kisspeptin (KP) on
serum LH. Five healthy male participants attended for eight separate
study visits at least a week apart and received vehicle, NAL, NKB, and
KP alone, and in combination in random order. One-hour baseline
blood sampling was conducted prior to starting the treatment. Ten-
minute blood sampling was continued from the start of the treatment
for 8 hours to measure gonadotrophins.
Figure 3. Effects of naltrexone (NAL), NKB, and kisspeptin (KP) on the
number of LH pulses. Five healthy male participants attended for eight
separate study visits at least a week apart and received vehicle, NAL,
NKB, and KP alone and in combination in random order. One-hour
baseline blood sampling was conducted prior to starting the
treatment. Ten-minute blood sampling was continued from the start of
the treatment for 8 hours to measure gonadotrophins. Deconvolution
analysis was used to determine the number of LH pulses.
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trend toward a rise in FSH comparedwith vehicle, but this
did not reach the 1% significance level (P  .03). NKB
alone had no significant effects on FSH release compared
with vehicle (P .99). The individual FSH results from all
participants are shown in Supplemental Figure 4.
Specific comparisons between the kisspeptin contain-
ing groups showed no significant difference with
NALKP (P  .44) compared with kisspeptin alone.
However, similarly to LH, there was significantly lower
increase in FSH with the NKBKP group compared with
kisspeptin alone (P  .003).
Testosterone
The rise in T levels in the treatment groups showed a
similar pattern to the rise in LH in each group (Supple-
mental Figure 5). There was a significant rise in T com-
paredwith vehicle for the groupsNAL,KP, andNALKP
(P  .001 vs vehicle) and a trend toward a rise in T over
vehicle but did not reach the 1% significance level in the
NKBKP (P  .04) and NALNKBKP (P  .03)
groups. Therewas no significant difference in T compared
with vehicle in the remaining groups (NALNKB, P 
.12; NKB, P  .2).
Specific comparisons between the kisspeptin-contain-
ing groups showed that the NKBKP group resulted in a
lower rise inT (similar to the lower rise inLHin this group)
compared with KP alone (P  .01). In addition, the
NALKP group showed a trend toward a greater rise T
(similar to the trend toward a greater rise in LH in this
group) compared with KP only (P .02). The individual
T results are shown in Supplemental Figure 6.
Estradiol
The rise in estradiol levels in the treatment groups
showed a similar pattern to the rise in T in each group
(Supplemental Figure 7). The KP and NALNKB groups
showed a significant increase in estradiol levels compared
with vehicle (P  .001). Other groups showed a trend
towards increasing estradiol compared to vehicle but did
not reach the 1% significance level (NAL, P  .02;
NALKP,P .14;NKBKP,P .07;NALNKBKP,
P .08). The NKB group did not show a rise in estradiol
compared with vehicle (P  .50).
Specific comparisons between the kisspeptin-contain-
ing groups showed a trend toward a lower estradiol in the
NKBKP group compared with kisspeptin alone (P .12)
and a trend toward a higher estradiol level in the NALKP
group compared with kisspeptin alone (P .05).
Discussion
Since the emergence of the KNDy neuron hypothesis for
regulating GnRH secretion and pulsatility, animal studies
have examined the interactions between the three neuro-
peptides. In this study we investigated the KNDy hypoth-
esis in humans for the first time by coadministration of
kisspeptin, NKB, and an opioid receptor antagonist, nal-
trexone, on gonadotropin release and LH pulsatility in
healthy male volunteers.
Although both kisspeptin and naltrexone administered
alone increased LH, their combined administration did
not significantly increase LH secretion or LH pulsatility
above that of kisspeptin alone. It is possible that kisspeptin
alone had maximally stimulated LH release and hence no
further increase occurred with coadministration of
NALKP. However, only the NALKP group caused a
significant rise in LH pulse amplitude, implicating opioid
inhibition in limiting the kisspeptin induced rise in LH
pulse amplitude. Animal studies have previously shown
that pretreatment with a KOR antagonist unmasked the
LH effects of senktide (NK3R agonist) (32, 33). In our
study, there were no effects of coadministration of an opi-
oid antagonist with NKB.
The data from volunteers who received combined
NKBKP revealed a novel interaction between NKB and
KP in humans. Our data suggest that coadministration of
NKB limited the ability of kisspeptin to stimulate a rise in
LH and FSH.
It is interesting to speculate about the mechanism by
which coadministrationofNKBmayhave limited the abil-
Figure 4. Effects of naltrexone (NAL), NKB, and kisspeptin (KP) on
ApEn. Five healthy male participants attended for eight separate study
visits at least a week apart and received vehicle, NAL, NKB, and KP
alone and in combination in random order. One-hour baseline blood
sampling was conducted prior to starting the treatment. Ten-minute
blood sampling was continued from the start of the treatment for 8
hours to measure gonadotrophins. Deconvolution analysis was used to
determine ApEn for each study. The ApEn is a measure of orderliness
of LH pulses (the lower the number, the more ordered the pulses in
the time series).
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ity of kisspeptin to stimulate a rise in LH in this human
study. It is obviously not possible to determine changes in
hypothalamic expression of neuropeptides after the acute
hormone infusion in humans. However, studies in rats
show that intra-ARC administration of senktide to ovari-
ectomized and estradiol-treated rats resulted in a reduc-
tion in GnRH1 and KISS1RmRNA expression in the me-
dial preoptic area (33). This suggests that ARCNKBmay
suppress GnRH secretion directly by reducing GnRH
transcription but also indirectly by reducing KISS1R (33).
Therefore, one could tentatively propose a mechanism in
which NKB in the presence of an abundance of kisspeptin
acts to inhibit GnRH secretion by affecting GnRH and
KISS1R transcription to reduce the actions of kisspeptin
on gonadotropin release.
NKB and kisspeptin have never been coinfused in hu-
mans previously, and relatively few animal studies have
investigated the effects of peripheral coadministration of
NKBKP. One previous study in male mice showed that
ip coadministration of NKBKP resulted in an approxi-
mately 20% lower rise in LH compared with when ip KP
was administered alone (30). Consistent with this in the
same study, the authors investigated the interaction be-
tween NKBKP in hypothalamic explants. They showed
thatNKBcausedno increase inGnRH,whereaskisspeptin
increasedGnRH;however, coadministrationofNKBKP
resulted in no increase in GnRH above basal state (30),
indicating that NKB inhibited the kisspeptin induced rise
in GnRH. This is similar to our findings in which coad-
ministration of NKBKP led to a lower rise of LH and
FSH when compared with kisspeptin administration
alone. The only other study that has investigated the ef-
fects of peripheral coadministration ofNKBKPwas per-
formed by Ramaswamy et al (34). They showed in GnRH
primed juvenile rhesus monkeys that a continuous iv in-
fusion of senktide or vehicle for 48 hours followed by iv
kisspeptin-10 resulted in a similar rise in LH. However,
this latter protocol was different from our study because
a 48-hour infusion of high-dose senktide was adminis-
tered to cause NK3R desensitization prior to kisspeptin
treatment, unlike in our study in which NKBKP were
coadministered acutely over an 8-hour study period.
Another important consideration is whether sex ste-
roid-negative feedback could have influenced our inter-
pretationof the gonadotropin results (35) because themen
in our study had normal testes that could respond to the
increases in LH secretion observed in some groups. Our
major findings were as follows: 1) alone and in combina-
tion, KP- and NAL-treated groups demonstrated an in-
crease in LH and LH pulsatility vs vehicle groups and 2)
NKBKP demonstrated attenuated gonadotropins vs KP
alone. If these findings were due to steroid-negative feed-
back, thenwewould have expected to observe a reduction
in T and estradiol in the KP- and NAL-treated groups vs
vehicle (therefore diminishing negative feedback) and to
observe an increase in T and estradiol in the NKBKP
groups vs KP alone (therefore increasing negative feed-
back effects). However, neither of these hypotheses were
evident in this time course. In fact, we observed that the
increases in T and estradiol mirrored the gonadotropin
changes in each group (Supplemental Figures 5–7). To-
gether these data suggest that the results observed in this
study were predominantly due to neuropeptide infusions
and opioid receptor blockade on gonadotropin release
rather than due to changes in steroid-negative feedback.
In this study we were also able to investigate the order-
liness of the LH pulses (ApEn). Our results suggest that
kisspeptin administration results in more ordered pulses,
whereas opioid blockade results in more disordered
pulses. In addition, kisspeptin may have amore dominant
role in determining the orderliness of LH pulses as when
kisspeptin is coadministered with naltrexone the effects
are to produce more ordered pulses (and the ability of
naltrexone to generate less ordered LH pulses are not
observed).
The aim of our study was to investigate the KNDy hy-
pothesis in humans for the first time, and our data reveal
interesting and novel interactions after the coadministra-
tion of kisspeptin, NKB, and naltrexone on gonadotropin
release and LH pulsatility in healthy male volunteers.
However, we need to be cautious in extrapolating our
findings to making definitive conclusions regarding the
role of the KNDy neurons in humans. This is because the
basis of the KNDy hypothesis is that the subpopulation of
arcuate neurons that colocalize kisspeptin, NKB, and
dynorphin interact together to affect pulsatile GnRH re-
lease. As such, many animal studies testing the KNDy hy-
pothesis haveused intracerebroventricular administration
of peptides directly into the central nervous system. This
is obviously not possible in humans, and we have used the
peripheral administrationofpeptides,whichmaynothave
full access to the central nervous system, although the
ARC is thought to have an incomplete blood-brain barrier
and its KNDy neurons extend to the median eminence,
which opens to the portal blood (36). In addition, kiss-
peptin and NKB have been demonstrated to have actions
on kisspeptin and NK3R receptors on GnRH neurones
extending into the median eminence and organum vascu-
losum lamina terminalis (9, 18, 37). Together this evi-
dence suggests that peripherally administered kisspeptin
and NKB can cross the blood-brain barrier sufficiently to
affectGnRHneuronal function.Consistentwith this, data
in the current study show that kisspeptin and NKB were
able tomodulate LHpulsatility and gonadotropin release.
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Although kisspeptin, NKB, and naltrexone were admin-
istered peripherally, studies have shown that they have
little direct effect on the pituitary gland but exert their
effects on GnRH secretion above the level of the pituitary
gland, which then subsequently determines pituitary go-
nadotropin secretion (9, 38, 39).
In this study we have been cautious in our interpreta-
tion of the results by using a 1% significance level (rather
than the traditional 5% significance level) to define sta-
tistical significance. This was used on the advice our stat-
istician (P.B.) to account for the relatively large number of
combinations between pairs of groups.A limitation of this
approach is that subtle interactions may have not been
identified.However, theadvantageof this approach is that
the statistically significant findings presented in this study
are robust.
In summary, our study has shown for the first time in
humans the important interactions of KNDy signaling in
regulating GnRH release and pulsatility (using LH as a
surrogate marker). This has important implications not
only for improvingourunderstandingofGnRHpulse gen-
eration in humans but also in optimizing novel hormonal
therapeutic agents to treat reproductive disorders.
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